Articles Tagged With: Pharmacology
-
The Trouble with Electronically Tracking Study Medications
Digital pills allow data to be recorded automatically about patients’ medication adherence, but patients and providers have expressed significant ethical concerns.
-
Predicting the Tolerability of Sacubitril/Valsartan in Advanced Heart Failure
An analysis of the sacubitril/valsartan run-in period for chronic, advanced heart failure patients showed 18% could not tolerate the lowest dose, usually because of hypotension or renal dysfunction. Investigators identified six predictors of non-tolerance, which may help clinicians choose the best candidates.
-
Are SGLT2 Inhibitors Effective for HFpEF Patients Without Diabetes?
After comparing empagliflozin vs. placebo for patients with heart failure and preserved left ventricular ejection fraction, researchers found no differences in the significant reduction of the primary outcome of cardiovascular death or heart failure hospitalization over 36 months based on whether patients were diabetic.
-
Orthopedic Surgeons Say ‘Open-Label’ Placebos Are Ethical, Yet Few Use Them
-
Fluvoxamine Reduces the Risk for Hospitalization from COVID-19
Researchers found fluvoxamine (100 mg twice a day for 10 days) lowered the risk for hospitalization among high-risk outpatients diagnosed with COVID-19.
-
AAN Offers Ethical Guidance on Alzheimer’s Drug
Neurology experts issue caution on costs, side effects regarding the approved-but-controversial Aduhelm.
-
Finerenone Tablets (Kerendia)
Finerenone can be prescribed to lower the risk of sustained estimated glomerular filtration rate decline, cardiovascular death, non-fatal myocardial infarction, end-stage kidney disease, and hospitalization from heart failure in adults with chronic kidney disease associated with type 2 diabetes. -
Ethical Controversy Erupts Over Alzheimer’s Drug Approval
The first new Alzheimer’s drug to be approved in almost 20 years has sparked a major ethical controversy, leading to protest resignations, criticism, qualifying statements, and even calls for investigations. -
Anticoagulation Plus Antiplatelet Therapy in Chronic Atherosclerosis
An analysis of the COMPASS trial for the secondary endpoint of mortality showed the combination of low-dose rivaroxaban and aspirin significantly lowered the all-cause mortality rate vs. low-dose aspirin alone. -
Aducanumab-avwa Injection (Aduhelm)
The FDA has approved a new, but controversial, treatment for Alzheimer’s disease.